FDA Granted Pediatric Disease Designation for OXi-4503
September 16, 2020 09:00 ET
|
Mateon Therapeutics
AGOURA HILLS, Calif., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics “Mateon” (OTCQB: MATN), a leading developer of TGF-β therapeutics for oncology and COVID-19, announced today that the US...
Mateon’s Global Study for Artemisinin Intervention Against COVID-19 Cleared for Patient Enrollment in India
September 14, 2020 07:00 ET
|
Mateon Therapeutics
AGOURA HILLS, Calif., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics “Mateon” (OTC.QB: MATN), a leading developer of TGF-β therapeutics for oncology and COVID-19, announced today that its...
Mateon Therapeutics Closes $2.0 Million Financing
July 27, 2020 07:00 ET
|
Mateon Therapeutics
AGOURA HILLS, Calif., July 27, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTC.QB: MATN) announced the closing of the 1st tranche of financing related to the Mateon operations and spinoff of its...
Mateon and Asili Research Alliance Enter Into Partnership for the Development of Artemisinin Against Covid-19
July 20, 2020 07:00 ET
|
Mateon Therapeutics
AGOURA HILLS, Calif., July 20, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, announced today the launch of its global observational study...
Mateon Therapeutics to fund observational studies of Artemisinin in developing countries
July 13, 2020 07:00 ET
|
Mateon Therapeutics
AGOURA HILLS, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, announced today that it will fund observational studies for...
Mateon is Selected by IBM Watson Health for the Use of IBM Clinical Development Solution at No Cost for Phase II Clinical Trial of OT-101 for COVID-19
June 24, 2020 07:00 ET
|
Mateon Therapeutics
AGOURA HILLS, Calif., June 24, 2020 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic”), a wholly owned subsidiary of Mateon Therapeutics Inc. (OTCQB:MATN) dedicated to the development of innovative...
Mateon Therapeutics Selects IQVIA for its Randomized, Controlled, Multi-Center Clinical Study to Test OT-101 as a Treatment for COVID-19 Patients
June 23, 2020 07:00 ET
|
Mateon Therapeutics
AGOURA HILLS, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, has selected IQVIA to manage C001, a Phase 2 randomized,...
Mateon and GMP Completed Research and Service Agreement
June 22, 2020 08:00 ET
|
Mateon Therapeutics
AGOURA HILLS, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon” or the “Company”) (OTCQB:MATN) announces that both Golden Mountain Partners (GMP) and Mateon have...
Mateon Announces Achievement of Milestone Under Licensing of OT-101/IL-2 Combination to Autotelic BIO
June 10, 2020 08:00 ET
|
Mateon Therapeutics
The licensing agreement of OT-101 to Autotelic BIO with the field of use limited to OT-101 (Trabedersen) with Interleukin-2 (OT-101/IL-2) combination became effective this week with the completion of...
Mateon Announces an Expansion to its Pharmaceutical Manufacturing AI Camera Grid by Including Contact Tracing to Ensure Worker Safety
June 08, 2020 05:00 ET
|
Mateon Therapeutics
TracePoint vision grid will identify workers who came in contact with a sick coworker and alert operational staff.Mateon’s patented AI camera grid system is similar to Amazon’s technology but at a...